Across TCGA pan-cancer cohorts, NUDT8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NUDT8 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher NUDT8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NUDT8 expression acts as an unfavorable survival marker.
DLBC, UCEC, and LUAD are the cancer types where NUDT8 Mutation most reproducibly stratifies survival.